Latest Annual Report
Filed: 2026-03-09
Key Insights
- The company has entered into several collaboration agreements, including with Tallac Therapeutics and Selexis SA, which could expand its pipeline and revenue opportunities.
- ALX Oncology has been actively issuing shares through at-the-market offerings, which could provide additional capital to fund its operations and development efforts.
- The company has granted performance-based restricted stock units and stock options as part of its compensation programs, which could align employee incentives with shareholder value creation.